JNJ-68284528、多発性骨髄腫の参加者におけるB細胞成熟抗原(BCMA)に対するキメラ抗原受容体T細胞(CAR-T)療法の研究 (CARTITUDE-2)
多発性骨髄腫患者のBCMAに対するキメラ抗原受容体T細胞(CAR-T)療法であるJNJ-68284528の第2相マルチコホート非盲検試験
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
調査の概要
状態
条件
研究の種類
入学 (実際)
段階
- フェーズ2
アクセスの拡大
連絡先と場所
研究場所
-
-
California
-
San Diego、California、アメリカ、92037
- University Of California San Diego
-
San Francisco、California、アメリカ、94143
- University of California San Francisco
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06510
- Yale University School Of Medicine
-
-
Florida
-
Tampa、Florida、アメリカ、33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory University
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Chicago、Illinois、アメリカ、60637
- University of Chicago
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Westwood、Kansas、アメリカ、66205
- University of Kansas Cancer Center
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40207
- Norton Cancer Institute
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- Dana Farber Cancer Institute
-
-
Michigan
-
Detroit、Michigan、アメリカ、48201
- Barbara Ann Karmanos Cancer Institute
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic Rochester
-
-
Missouri
-
St Louis、Missouri、アメリカ、63108
- Washington University School Of Medicine
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
New York、New York、アメリカ、10065
- Memorial Sloan-Kettering Cancer Center
-
New York、New York、アメリカ、10029
- Mount Sinai Medical Center
-
The Bronx、New York、アメリカ、10467
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- Levine Cancer Institute, Carolinas HealthCare System
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Oregon Health And Science University
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19107
- Thomas Jefferson University
-
Pittsburgh、Pennsylvania、アメリカ、15232
- University of Pittsburgh
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- University of Texas Southwestern Medical Center
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- University of Utah
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- University of Virginia
-
Richmond、Virginia、アメリカ、23298
- Virginia Commonwealth University - Massey Cancer Center
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53705
- University of Wisconsin Carbone Cancer Center
-
-
-
-
-
Ramat Gan、イスラエル、52621
- Sheba Medical Center Tel Hashomer
-
Tel Aviv、イスラエル、64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Amsterdam、オランダ、1081 HV
- VU Medisch Centrum
-
Groningen、オランダ、9713 GZ
- University Medical Center Groningen
-
-
-
-
-
Riyadh、サウジアラビア、11211
- King Faisal Specialist Hospital & Research Center
-
-
-
-
-
Pamplona、スペイン、31008
- Clinica Univ. de Navarra
-
Salamanca、スペイン、37007
- Hosp Clinico Univ de Salamanca
-
-
-
-
-
Hamburg、ドイツ、20246
- Universitaetsklinikum Hamburg Eppendorf
-
Würzburg、ドイツ、97080
- Universitatsklinikum Wurzburg
-
-
-
-
-
Lille、フランス、59037
- CHRU de Lille Hopital Claude Huriez
-
Nantes、フランス、44093
- C.H.U. Hotel Dieu - France
-
Paris、フランス、75475
- Hopital Saint Louis
-
-
-
-
-
Ghent、ベルギー、9000
- UZ Gent
-
Leuven、ベルギー、3000
- UZ Leuven
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Cohort A: Received a minimum of 1 to a maximum of 3 prior lines of therapy including a proteasome inhibitor (PI) and immunomodulatory therapy (IMiD), and lenalidomide refractory per International Myeloma Working Group (IMWG) guidelines
- Cohort B: Received one line of prior therapy including a PI and an IMiD, and disease progression per IMWG criteria less than or equal to (<=) 12 months after treatment with autologous stem cell transplantation (ASCT) or <=12 months from the start of anti-myeloma therapy for participants who have not had an ASCT
- Cohort C: Previously treated with a PI, an IMiD, an anti-CD38 monoclonal antibody and B-cell maturation antigen (BCMA)-directed therapy
- Cohort D: Newly diagnosed multiple myeloma per IMWG with a history of 4 to 8 total cycles of initial therapy, including induction, high-dose therapy, and ASCT with or without consolidation
- Cohort E: Have newly diagnosed multiple myeloma without prior therapy (one cycle of prior therapy before enrollment is acceptable) and classified as high risk defined as either: 1) International Staging System (ISS) stage III criteria, Beta 2 microglobulin greater than or equal to (>=) 5.5 milligrams per liter (mg/L) (via local or central laboratory assessment) or 2) high risk cytogenetic features del(17/17p), t (14;16), t(14;20), 1q amplification (at least 4 total copies) in at least 20 percent (%) of the total plasma cell population
- Cohort F:
- Participant must have a documented efficacy response of very good partial response (VGPR) or better, without progressive disease prior to enrollment, as assessed per IMWG 2016 criteria
- Received initial therapy as specified below. The dose/schedule of cycles administered will be as per standard of care. It is acceptable for up to 1 cycle of the protocol-specified regimens to be missing one of the listed agents (example, held due to toxicity). Acceptable combinations include: At least 5 to 8 cycles of initial therapy with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd). The dose/schedule of cycles administered will be as per standard of care or; at least 4 to 8 cycles of initial therapy with daratumumab, lenalidomide and dexamethasone (D-Rd) or; at least 4 to 8 cycles of initial therapy with a carfilzomib-based triplet or quadruplet regimen
- For US sites only: Cohort G: Not considered for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to: a) Ineligibility due to advanced age; or b) Ineligibility due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT; or c) Subject refusal of high-dose chemotherapy with ASCT as initial treatment
- Cohorts A, B, C, E and Cohort G (for US sites only):
- Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) or urine M-protein level >=200 milligrams (mg)/24 hours
- Light chain multiple myeloma in whom only measurable disease is by serum free light chain (FLC) levels in the serum: Serum immunoglobulin FLC >=10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio
- Cohort A: For participants with neither serum nor urine measurable disease, baseline positron emission tomography/ computed tomography (PET/CT) or whole -body magnetic resonance imaging (MRI) may be used to satisfy the measurable disease criteria. A minimum of one lesion with a bi-dimensional measurement of at least 1 centimeter (cm)*1 cm is required
- Cohorts B, C: For participants with neither serum nor urine measurable disease, baseline positron emission tomography/ computed tomography (PET/CT) or whole body magnetic resonance imaging (MRI) may be used to satisfy the measurable disease criteria
- Cohorts A, B, C, D, E, F and Cohort G (for US sites only): Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
Exclusion Criteria:
- Cohorts A, B, D, F: Any therapy that is targeted to BCMA
- Cohorts A, B, C, D, F: Prior treatment with chimeric antigen receptor T (CAR-T) therapy directed at any target
- Cohorts A, B, C, D, F:
- Ongoing toxicity from previous anticancer therapy must resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy
- Received a cumulative dose of corticosteroids equivalent to >=70 mg of prednisone within the 7 days (Cohort A, B, C, F) or 14 days (Cohort D) prior to apheresis
- Serious underlying medical condition, such as (a) evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection; (b) active autoimmune disease or a history of autoimmune disease within 3 years; (c) overt clinical evidence of dementia or altered mental status; (d) any history of Parkinson's disease or other neurodegenerative disorder
- Cohorts A, B, C, D, E, F: Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma
- Cohort F and Cohort G (for US sites only): Active malignancies (that is, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are: a) non-muscle invasive bladder cancer treated within the last 24 months that is considered completely cured; b) skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured; c) non-invasive cervical cancer treated within the last 24 months that is considered completely cured; d) localized prostate cancer (N0M0): with a Gleason score of greater than or equal to (=>)6, treated within the last 24 months or untreated and under surveillance, with a Gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence, or history of localized prostate cancer and receiving androgen deprivation therapy and considered to have a very low risk of recurrence, e) breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in situ, or history of localized breast cancer and receiving antihormonal agents and considered to have a very low risk of recurrence; f) malignancy that is considered cured with minimal risk of recurrence
- Cohort E and Cohort G (for US sites only): Frailty index of >= 2 according to Myeloma Geriatric Assessment score
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:JNJ-68284528
Single group assignment-Post lymphodepletion, JNJ-68284528 single infusion given to Part A participants: Cohort A (Progressive disease post 1-3 prior lines of therapy), Cohort B (Early relapse post front-line), Cohort C(Relapsed/refractory multiple myeloma post PI, IMiD,anti-CD38,anti-BCMA therapy), Cohort D(Less than CR post ASCT front-line therapy, some participants will receive JNJ-68284528 then lenalidomide), Cohort F(Newly diagnosed multiple myeloma [NDMM], standard risk [International Staging System Stage I/II] and post initial therapy); Cohort E(NDMM,transplant not planned, high risk disease) will first receive quadruplet induction regimen of daratumumab, bortezomib, lenalidomide and dexamethasone(D-VRd) then lymphodepletion and JNJ-68284528 then consolidation regimen of lenalidomide. Enrollment is closed for Cohorts A,B,C,D,E and F. For US sites only: Part B:Cohort G (NDMM, transplant not planned) will receive daratumumab, lenalidomide and dexamethasone followed by cilta-cel. |
Participants in Cohorts A,B,C, D, E, F and Cohort G (for US sites only) will receive JNJ-68284528 intravenously.
他の名前:
Some participants in Cohort D and all participants in Cohorts E and Cohort G (for US sites only) will also receive lenalidomide capsules orally. Participants in Cohorts E and Cohort G (for US sites only) will also receive daratumumab subcutaneous (SC) injection. Participants in Cohorts E will also receive bortezomib subcutaneously. Participants in Cohorts E and Cohort G (for US sites only) will also receive dexamethasone orally or intravenously. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cohorts A, B, C, D, E, and F: Percentage of Participants with Negative Minimal Residual Disease (MRD)
時間枠:At least 1 year after JNJ-68284528 infusion on Day 1
|
MRD negative rate is the percentage of participants who achieve MRD negative status by evaluation of bone marrow aspirate as defined by the International Myeloma Working Group (IMWG) criteria. |
At least 1 year after JNJ-68284528 infusion on Day 1
|
|
For US sites only: Cohort G: Percentage of Participants with Sustained MRD Negative Complete Response (CR)
時間枠:At least 1 year after JNJ-68284528 infusion on Day 1
|
Sustained MRD-negative CR is defined as participants with CR or better who sustain MRD-negative status, as determined by next-generation sequencing (NGS) or next generation flowcytometry (NGF) with sensitivity of 10^-5, for at least 12 months without any examination showing MRD positive status or progressive disease in between. |
At least 1 year after JNJ-68284528 infusion on Day 1
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Response Rate (ORR)
時間枠:Up to 8 years and 10 months
|
ORR is defined as the percentage of participants who achieve a partial response (PR) or better according to the IMWG criteria. |
Up to 8 years and 10 months
|
|
Cohorts A, B, C, D, E, and F: VGPR or Better Rate
時間枠:Up to 8 years and 10 months
|
The VGPR or better rate (stringent complete responses [sCR] + complete response [CR] + VGPR), defined as the percentage of participants achieving VGPR or better response according to IMWG criteria during or after the study treatment. |
Up to 8 years and 10 months
|
|
Cohorts A, B, C, D, E, and F: Clinical Benefit Rate (CBR)
時間枠:Up to 8 years and 10 months
|
CBR is defined as the percentage of participants who achieve ORR (sCR + CR + VGPR + PR) + minimal response (MR) according to the IMWG criteria. |
Up to 8 years and 10 months
|
|
Duration of Response (DOR)
時間枠:Up to 8 years and 10 months
|
DOR will be calculated among responders from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG criteria. |
Up to 8 years and 10 months
|
|
Time to Response (TTR)
時間枠:Up to 8 years and 10 months
|
TTR is defined as the time from the date of the initial infusion of JNJ-68284528 and the first efficacy evaluation that the participant has met all criteria for PR or better. |
Up to 8 years and 10 months
|
|
Cohorts A, B, C, D, E, and F: MRD Negative Rate at 12 Months for Participants who Achieve a Complete Response (CR)
時間枠:12 months
|
MRD negative rate at 12 months for participants who achieved a complete response (CR) is defined as the percentage of participants who are MRD negative by bone marrow aspirate and meet the IMWG criteria for CR at 12 months after initial dose of JNJ-68284528 and before disease progression or starting subsequent therapy including retreatment of JNJ-68284528. |
12 months
|
|
Time to MRD Negativity
時間枠:Up to 8 years and 10 months
|
Time to MRD negativity will be calculated in participants who are MRD negative by bone marrow aspirate from the date of the initial infusion of JNJ-68284528 to the initial date of reaching the MRD negative status. |
Up to 8 years and 10 months
|
|
Duration of MRD Negativity
時間枠:Up to 8 years and 10 months
|
Duration of MRD negativity will be calculated among participants who are MRD negative by bone marrow aspirate from the date of initial MRD negativity to the date when MRD is detected at the same threshold (10^-5). |
Up to 8 years and 10 months
|
|
Cohorts A, B, C, D, E, and F: MRD Negative Rate Across Clinical Response
時間枠:Up to 8 years and 10 months
|
MRD negative rate across clinical response groups will be assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR) or very good partial response (VGPR) according to the IMWG criteria during or after the study treatment. MRD negative rate is defined as the percentage of participants who have negative MRD by bone marrow aspirate at any timepoint. |
Up to 8 years and 10 months
|
|
Number of Participants with Adverse Events by Severity
時間枠:Up to 8 years and 10 months
|
An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), with the exception of cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS and ICANS will be evaluated according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading. |
Up to 8 years and 10 months
|
|
Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability
時間枠:Up to 8 years and 10 months
|
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. |
Up to 8 years and 10 months
|
|
Number of Participants with Laboratory Abnormalities
時間枠:Up to 8 years and 10 months
|
Number of participants with laboratory abnormalities will be reported. |
Up to 8 years and 10 months
|
|
Number of Participants with Vital Signs Abnormalities
時間枠:Up to 8 years and 10 months
|
Number of participants with vital signs abnormalities will be reported. |
Up to 8 years and 10 months
|
|
Cohorts A, B, C, D, E, and F: Levels of B-Cell Maturation Antigen (BCMA) Expressing Cells and Soluble BCMA
時間枠:Up to 1 year
|
Levels of expression of BCMA-expressing plasma cells in the bone marrow as well as the level of soluble BCMA in blood will be reported. |
Up to 1 year
|
|
Cohorts A, B, C, D, E, and F: Systemic Inflammatory Cytokine Concentrations
時間枠:Up to 1 year
|
Blood cytokine concentrations (Interleukin [IL]-6, IL-15, IL-10, and Interferon [IFN-gamma]) will be measured for biomarker assessment. |
Up to 1 year
|
|
Cohorts A, B, C, D, E, and F: Levels of JNJ-68284528 T Cell Expansion (proliferation), and Persistence
時間枠:Up to 1 year
|
Levels of JNJ-68284528 T cell expansion (proliferation), and persistence via monitoring CAR-T positive cell counts and CAR transgene level will be reported. |
Up to 1 year
|
|
Cohorts A, B, C, D, E, and F: Number of Participants with Anti-JNJ-68284528 Antibodies
時間枠:Up to 1 year
|
Number of participants exhibiting anti-drug antibodies for JNJ-68284528 will be reported. |
Up to 1 year
|
|
For US sites only: Cohort G: Percentage of Participants with Complete Response (CR) or Better
時間枠:Up to 8 years and 10 months
|
CR or better is defined as the percentage of participants achieving CR or sCR prior to subsequent antimyeloma therapy in accordance with the IMWG criteria during or after the study treatment. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Percentage of Participants with MRD-negative CR or sCR
時間枠:Up to 8 years and 10 months
|
MRD-negative CR/sCR is defined as the percentage of participants who achieve MRD-negative status, as determined by NGS/NGF with sensitivity of 10^-5, at any time after enrollment and prior to progressive disease or subsequent antimyeloma therapy and who achieve CR/sCR or better. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Progression-free Survival on Next-line Therapy (PFS2)
時間枠:Up to 8 years and 10 months
|
PFS2 is defined as the time interval between the start of study treatment and date of event, which is defined as death from any cause or PD as assessed by investigator that starts after the next line of therapy, whichever occurs first. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Overall Survival (OS)
時間枠:Up to 8 years and 10 months
|
OS is defined as the time from the start of study treatment to the date of the participant's death. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Progression-free Survival (PFS)
時間枠:Up to 8 years and 10 months
|
PFS is defined as the time from the start of study treatment to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause, whichever occurs first. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Number of Participants with Measurable Replication Competent Lentivirus (RCL) in Whole Blood
時間枠:Up to 8 years and 10 months
|
Number of participants with measurable RCL in whole blood will be reported. |
Up to 8 years and 10 months
|
|
For US sites only: Cohort G: Time to Subsequent Anti-Myeloma Therapy
時間枠:Up to 8 years and 10 months
|
Time to subsequent anti-myeloma treatment is defined as the time from start of study treatment to the start of subsequent anti-myeloma treatment. |
Up to 8 years and 10 months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 血管疾患
- 心血管疾患
- 新生物
- 免疫系疾患
- 組織型別の新生物
- 血液疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- 新生物、形質細胞
- 止血障害
- パラタンパク血症
- 血液タンパク質障害
- 出血性疾患
- ヘミックおよびリンパ疾患
- 多発性骨髄腫
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- カルボン酸
- 多環式化合物
- ピペリジン
- 無機化学物質
- 妊娠
- 妊娠
- ステロイド
- 融合リング化合物
- ステロイド、フッ素化
- 妊娠症
- ボロン酸
- 酸、非カルボン酸
- 酸
- ホウ素化合物
- ピラジン
- フタリミド
- フタル酸
- 酸、炭素環
- ピペリドン
- イソインドール
- レナリドミド
- ボルテゾミブ
- デキサメタゾン
- ダラトゥムマブ
その他の研究ID番号
- CR108581
- 2018 (米国 NIH グラント/契約)
- 2018-004124-10 (EudraCT番号)
- 68284528MMY2003 (その他の識別子:Janssen Research & Development, LLC)
- 2023-506587-13-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。